Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E17.55 EPS (ttm)9.06 Insider Own0.10% Shs Outstand760.74M Perf Week-2.73%
Market Cap120.95B Forward P/E13.07 EPS next Y12.16 Insider Trans-2.56% Shs Float746.99M Perf Month3.13%
Income6.94B PEG2.16 EPS next Q2.76 Inst Own82.30% Short Float1.18% Perf Quarter4.81%
Sales21.66B P/S5.58 EPS this Y35.20% Inst Trans0.19% Short Ratio2.48 Perf Half Y0.20%
Book/sh37.34 P/B4.26 EPS next Y9.84% ROA9.80% Target Price182.06 Perf Year1.30%
Cash/sh41.25 P/C3.85 EPS next 5Y8.12% ROE25.20% 52W Range128.54 - 178.81 Perf YTD-1.38%
Dividend4.00 P/FCF20.05 EPS past 5Y13.60% ROI12.50% 52W High-11.09% Beta0.82
Dividend %2.52% Quick Ratio4.20 Sales past 5Y7.60% Gross Margin80.50% 52W Low23.69% ATR2.94
Employees17900 Current Ratio4.40 Sales Q/Q3.80% Oper. Margin39.10% RSI (14)53.94 Volatility2.06% 1.80%
OptionableYes Debt/Eq1.12 EPS Q/Q40.90% Profit Margin32.00% Rel Volume0.68 Prev Close158.30
ShortableYes LT Debt/Eq1.04 EarningsApr 28 AMC Payout34.50% Avg Volume3.56M Price158.99
Recom2.50 SMA20-0.53% SMA504.58% SMA2003.33% Volume2,433,172 Change0.44%
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
May-02-16 04:52PM  AMGEN INC Files SEC form 10-Q, Quarterly Report EDGAR Online
03:47PM  Aside From 1 Eyesore, Amgen Delivers Another Solid Quarter at Motley Fool
03:22PM  Biotech ETFs Sink on Mixed Q1 Results Zacks
11:06AM  2 Dirt-Cheap Big Pharma Stocks Poised to Beat Biotech's Bad Rap at TheStreet
10:45AM  Amgen, Inc. :AMGN-US: Earnings Analysis: Q1, 2016 By the Numbers at Capital Cube
May-01-16 10:50AM  Analysts Make Major Changes to Top Biotech Ratings at 24/7 Wall St.
Apr-29-16 05:15PM  Top Trades: Biotech's brutal week CNBC
05:00PM  5 way to trade the mixed biotech sector CNBC
04:50PM  US stocks hit by health care woes but avoid bigger losses AP
01:56PM  A Typical Bad First Quarter For Biotech: Leerink at Barrons.com
01:14PM  What Are Analysts Saying About Q1 At Biotech's Big 4? Amgen, Biogen, Celgene, Gilead at Forbes
09:14AM  Amgen (AMGN) Tops Q1 Earnings & Revenues, Ups View Zacks
08:32AM  Pfizer Earnings Could Highlight Enbrel and Lyrica Sales Decline Yahoo Finance Contributors
08:00AM  Early movers: AMZN, VRX, TIVO, TYC, DAL, VFC, MCO, NWL, BUD & more at CNBC
01:51AM  Edited Transcript of AMGN earnings conference call or presentation 28-Apr-16 9:30pm GMT Thomson Reuters StreetEvents
Apr-28-16 08:16PM  Amgen posts 1Q sales, profit jumps, raises profit forecasts AP
07:20PM  Amgen profit sails past Street expectations; raises 2016 outlook Reuters
05:59PM  Q1 Earnings Reports Continue the Deluge: AMZN, GILD, AMGN Zacks
05:46PM  [$$] Amgen Profit Rises 17%, Guidance Raised at The Wall Street Journal
05:41PM  Amgen (AMGN) Beats Q1 Earnings Estimates, Raises 2016 Outlook Zacks
05:37PM  After Hours: Amazon, LinkedIn, Baidu, Expedia Soar, Gilead Flops at Investor's Business Daily
05:30PM  Amgen Inc Earnings Call scheduled for 5:30 pm ET today CCBN
05:13PM  Amgen Legacy Drugs Drive Q1 Beat; Gilead Hep C Juggernaut Stumbles at Investor's Business Daily
04:40PM  AMGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:24PM  Amgen (AMGN) Stock Higher in After-Hours Trading on Q1 Beat, Guidance at TheStreet
04:21PM  Amgen beats Street 1Q forecasts AP
04:08PM  Amgen profit tops Street expectations; raises 2016 outlook Reuters
04:07PM  Beat & raise for Amgen CNBC
04:01PM  Amgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90 PR Newswire
04:01PM  Amgen Tops Sales and Profit Estimates, Boosts 2016 Forecast at Bloomberg
12:00PM  Biotech Boom May Continue Through Earnings Season Benzinga
11:35AM  Pressure From Japan: Interest Rate Decision Weighs, But Earnings In Focus Benzinga
07:07AM  Q1 2016 Amgen Inc Earnings Release - After Market Close CCBN
Apr-27-16 09:05AM  4 Biotech Stocks Reporting on Apr 28: AMGN, GILD, ALXN, CELG Zacks
08:10AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
Apr-26-16 02:53PM  Stocks Are Mixed as Oil Jumps 3% at TheStreet
08:08AM  Big Biotech In The Earnings Spotlight Benzinga
06:25AM  One Year Later: Whatever Happened To Those Biotech Companies? at Forbes
Apr-25-16 10:37PM  These Are The Companies Reporting Earnings This Week Yahoo Finance Contributors
05:30PM  Amgen Announces Webcast Of 2016 First Quarter Financial Results PR Newswire
02:42PM  5 Biotech Stocks to Bet on This Earnings Season Zacks
01:02PM  3 Data Points That Will Likely Define Amgen's First-Quarter Report on April 28 at Motley Fool
10:58AM  Healthcare Q1 Earnings Look Solid: ETFs to Benefit Zacks
09:00AM  Amgen To Participate In The 2016 World Medical Innovation Forum On Cancer PR Newswire
08:30AM  Amgen (AMGN) May Beat Q1 Earnings: Will the Stock Gain? Zacks
Apr-24-16 01:07PM  Billionaire Dan Loebs Top Picks Register Disappointing Returns at Insider Monkey
Apr-22-16 06:49PM  Does Biotechs Recent Bounce Have Legs? Gurufocus
Apr-20-16 04:38PM  Biotech Stock Roundup: Medivation Buyout Rumors Resurface, Synta Up on Merger Deal Zacks
03:10PM  Why It May Be Time to Get Bullish on Biotech Yahoo Finance Contributors
01:41PM  Breakthrough cholesterol drugs fizzle amid price pushback AP
12:29PM  Why Biotech Will Benefit from Higher Drug Prices at Barrons.com
11:50AM  Amgen's (AMGN) Phase III Study Results on Nplate Published Zacks
10:21AM  20 Reasons to Buy Amgen and Never Sell at Motley Fool
Apr-19-16 04:00PM  Nplate® (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia PR Newswire
01:12PM  [$$] Britain can build a biotech industry to match its Nobel winners at Financial Times
12:54PM  Why Johnson & Johnson's Earnings are Good News for Big Biotech at Barrons.com
12:52PM  [Podcast] Biotech Analyst: Why revenue should be the focus for Q1 and how the upcoming election will impact names in the space
11:31AM  Wall Street is Dead Wrong: Why It's Time to Buy Illumina
Apr-18-16 09:39AM  Medivation: It's Not Just M&A at Barrons.com
08:18AM  Will MS Franchise Sales Boost Biogen's (BIIB) 1Q Earnings?
Apr-15-16 12:19PM  Biotech: Why Earnings Might Be Better Than You Think at Barrons.com
11:22AM  [$$] Best Bets in Biopharma at Barrons.com
03:00AM  CAIBX: Portfolio Trends in 2016 at Investopedia
Apr-14-16 05:45PM  This is the most expensive drug in America at MarketWatch
04:58PM  The Best And Worst Stocks Of The 2008 Crash: What We Learned
01:32PM  Gilead Sciences: Maybe It'll Beat After All? at Barrons.com
10:39AM  Spending On Drugs Will Drop As Top Sellers Go Generic at Forbes
07:04AM  Why Has Teva Pharmaceutical Targeted Orphan Diseases?
Apr-13-16 03:39PM  3 Biotech Takeover Targets That Could Get Bought Soon at Motley Fool
01:52PM  [$$] Forbion Capital Gathers EUR183M for Third Life Sciences Fund at The Wall Street Journal
01:20PM  This is Why Everyone Wants to Buy Medivation at Barrons.com
12:01AM  Sean Parker sets up $250 mln cancer immunotherapy collaboration
Apr-12-16 06:41PM  Medivation: Biotech's Most Wanted? at Barrons.com
01:24PM  How Regenerons Eylea Growth, Amgen, Sanofi Deal Figure In Stock
11:51AM  Biotech: If M&A is the Answer, What's the Question? at Barrons.com
09:55AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
Apr-11-16 03:30PM  Novartis Binocrit's Subcutaneous Formula Gets EC Approval
11:44AM  Shares of Regeneron Pharmaceuticals, Inc. Struggled in March -- Here's Why at Motley Fool
11:38AM  2 Big Pharma Stocks That Offer Market-Beating Growth Amid Turmoil at TheStreet
05:14AM  Politicians Impede Prosperity
Apr-06-16 09:34PM  Jefferies' Global Equity Adds Risk, Rotates Into EM, Cyclicals at Barrons.com
02:26PM  Biotech: The Waiting Game? at Barrons.com
01:33PM  Cherry picking stocks
12:05PM  Your Horizon Breakdown: Performance across Segments
10:50AM  Pfizer's (PFE) Biosimilar of Remicade Receives FDA Approval
09:08AM  Regenerons Stock Reacts to Dupilumab Phase 3 Trials
03:36AM  FSPHX: Fidelity Select Healthcare Fund's Top 5 Holdings Analysis at Investopedia
Apr-05-16 06:12PM  [$$] FDA Approves Rheumatoid Arthritis Knockoff at The Wall Street Journal
06:06PM  FDA approves 1st cheaper version of J&J's top drug Remicade
04:21PM  This Amgen News Could Be a Game-Changer in its Fight Against Sanofi and Regeneron Pharmaceuticals at Motley Fool
07:22AM  Forget Regeneron Pharmaceuticals, Inc.: These 2 Stocks Are Better Buys at Motley Fool
Apr-04-16 05:28PM  Pfizer's PCSK9 Inhibitor Positive in Second Phase III Study
03:25PM  A Biotech Breakout? at Barrons.com
12:22PM  Biotech: Time to Buy? at Barrons.com
10:01AM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Amgen at Motley Fool
Apr-03-16 07:00PM  Samsung brings in the lawyers for biosimilars push
11:37AM  [$$] Drugmakers race to prescribe preventive migraine remedies at Financial Times
11:05AM  Some People Really Can't Take Statins For High Cholesterol, Scientists Prove at Forbes
09:05AM  Positive Efficacy And Tolerability Study Of Repatha® (evolocumab) In Statin-Intolerant Patients Published In "Journal of the American Medical Association" PR Newswire
Apr-02-16 02:03PM  The Secrets Out: These Biotech Marvels Have Fallen Too Far
Amgen Inc., a biotechnology company, engages in discovering, developing, manufacturing, and delivering human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its principal products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of high cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc.; UCB; Novartis AG; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM
HERRINGER FRANK CDirectorMar 14Option Exercise50.445,000252,20030,608Mar 16 06:48 PM
COFFMAN VANCE DDirectorMar 09Option Exercise50.445,000252,20043,447Mar 10 06:55 PM
Bradway Robert AChairman, CEO and PresidentMar 02Option Exercise50.4484,0004,236,960447,102Mar 04 06:07 PM
Bradway Robert AChairman, CEO and PresidentMar 02Sale146.4820,0002,929,566383,102Mar 04 06:07 PM
de Carbonnel FrancoisDirectorAug 31Sale153.845,000769,19215,150Sep 02 07:46 PM
Hassan FredDirectorAug 19Buy166.633,010501,5623,582Aug 20 05:58 PM
PELHAM JUDITH CDirectorJul 31Sale180.405,035908,31411,890Aug 04 06:31 PM
Patton Cynthia MSVP & CCOJun 02Sale157.064,530711,48216,571Jun 03 07:16 PM
Balachandran MadhavanEVP, OperationsMay 07Option Exercise55.7221,7501,211,94855,144May 11 04:56 PM
Balachandran MadhavanEVP, OperationsMay 07Sale157.8721,7503,433,69533,394May 11 04:56 PM